HepeX-B in Post Hepatic Allografts for Treatment of End Stage Liver Disease Due to Hepatitis B Infection
Status:
Terminated
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the use of HepeX-B versus HBIg, two anti-viral drugs,
in patients who have received liver transplants due to liver failure caused by Hepatitis B
infection. Patients will be evaluated over a 6 month to 1.5 year period to evaluate whether
or not the drugs prevent the Hepatitis B virus from infecting the new liver.